DV Trading LLC Boosts Stock Position in Compass Therapeutics, Inc. $CMPX

DV Trading LLC lifted its stake in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) by 1,649.8% in the first quarter, HoldingsChannel reports. The fund owned 423,566 shares of the company’s stock after acquiring an additional 399,359 shares during the period. DV Trading LLC’s holdings in Compass Therapeutics were worth $2,241,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. raised its stake in Compass Therapeutics by 3,933.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock worth $27,000 after acquiring an additional 7,592 shares during the period. Parallel Advisors LLC purchased a new position in Compass Therapeutics during the first quarter valued at approximately $28,000. Creative Planning bought a new position in shares of Compass Therapeutics in the second quarter worth approximately $30,000. Flagship Harbor Advisors LLC bought a new position in shares of Compass Therapeutics in the fourth quarter worth approximately $32,000. Finally, Strs Ohio purchased a new stake in shares of Compass Therapeutics in the first quarter worth $34,000. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Price Performance

Shares of CMPX opened at $1.91 on Friday. Compass Therapeutics, Inc. has a 1 year low of $1.61 and a 1 year high of $6.88. The company has a 50 day simple moving average of $2.12 and a two-hundred day simple moving average of $3.99. The firm has a market cap of $343.97 million, a P/E ratio of -4.66 and a beta of 0.90.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). On average, sell-side analysts anticipate that Compass Therapeutics, Inc. will post -0.42 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on CMPX. Citizens Jmp restated a “market outperform” rating and set a $10.00 price objective on shares of Compass Therapeutics in a research report on Tuesday, April 28th. D. Boral Capital reaffirmed a “buy” rating and issued a $30.00 target price on shares of Compass Therapeutics in a report on Monday, April 27th. Citigroup reiterated a “market outperform” rating on shares of Compass Therapeutics in a research note on Thursday, June 4th. Raymond James Financial cut Compass Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, April 28th. Finally, Wall Street Zen cut Compass Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $12.25.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.